In February 2013, a near-bankrupt Cylex Inc was acquired by Viracor-IBT Laboratories Inc, a fellow SBIR recipient. Originally known as Biotechnology Transfer, Inc. (BTI), at that time, Cylex provided consulting and contract research services to industry and academia. Cylex® had been a life science company manufacturing and developing patented in vitro diagnostic products for the assessment of immunity. Products were of value to physicians treating life-threatening diseases or conditions who sought to optimize therapy through individualized management of a patients immune system: reducing side effects, improving clinical response and quality of life. ImmuKnow - the Cylex® Immune Cell Function Assay - intended to be used as an adjunct to post-transplantation drug level monitoring along with other clinical indicators. Cylexs patented platform technology also was designed to provide an innovative approach for measuring immune activity in AIDS and cancer patients, and those with infectious diseases, autoimmune or other immune system disorders. In early 2002, Cylex® received FDA clearance for ImmuKnow - the Cylex® Immune Cell Function Assay. The assay is used for the detection of cell-mediated immunity in an immunosuppressed population. Cylex has developed and patented a blood test for the measurement of immunity. In vitro CMI can be used to assess the efficacy of therapy used in the treatment of infectious diseases such as HIV and hepatitis, cancer, autoimmunity and transplantation.